Insider Transactions in Q1 2026 at Xilio Therapeutics, Inc. (XLO)
Insider Transaction List (Q1 2026)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 02
2026
|
Christopher James Frankenfield Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
7,030
-22.11%
|
$0
$0.64 P/Share
|
|
Jan 02
2026
|
Kevin M. Brennan SVP, FINANCE AND ACCOUNTING |
SELL
Open market or private sale
|
Direct |
1,826
-22.28%
|
$0
$0.64 P/Share
|
|
Jan 01
2026
|
Rene Russo PRESIDENT AND CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
44,250
+11.97%
|
-
|
|
Jan 01
2026
|
Christopher James Frankenfield Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
19,375
+37.86%
|
-
|
|
Jan 01
2026
|
Kevin M. Brennan SVP, FINANCE AND ACCOUNTING |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+37.89%
|
-
|
|
Jan 01
2026
|
Katarina Luptakova CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
16,625
+33.33%
|
-
|